The year 2025 witnessed significant developments in patent litigation across the United States, marked by a notable increase in case filings, substantial damages awards, and pivotal judicial decisions that have reshaped the legal landscape.
According to Lex Machina’s 2025 Patent Litigation Report, there was a 22% surge in patent case filings, bringing activity back in line with recent historical averages following a notable drop in 2023. This rebound was largely driven by an increase in filings from non-High-Volume Plaintiffs (non-HVPs), who filed over 16% more patent lawsuits in 2024 compared to the average annual rate from 2017 to 2023. Additionally, more than $4.3 billion in damages were awarded in patent claims in more than 90 cases, a 20% increase over the prior year. ([lexisnexis.com](https://www.lexisnexis.com/community/pressroom/b/news/posts/lex-machina-releases-2025-patent-litigation-report?utm_source=openai))
Design patent litigation experienced a 35% increase from 2023, with over 450 cases filed in 2024, demonstrating sustained growth. Similarly, Abbreviated New Drug Application (ANDA) patent litigation filings rose by more than 20%, marking the third consecutive annual increase and highlighting the ongoing importance of generic drug market access and pharmaceutical patent challenges. ([lexisnexis.com](https://www.lexisnexis.com/community/pressroom/b/news/posts/lex-machina-releases-2025-patent-litigation-report?utm_source=openai))
Venue preferences also shifted notably. The Eastern District of Texas reclaimed its position as the leading venue for patent plaintiffs, accounting for 27.7% of filings. The Western District of Texas followed with 11.5%, and the District of Delaware with 11.4%. This resurgence underscores the strategic considerations influencing plaintiffs’ choices in filing jurisdictions. ([unifiedpatents.com](https://www.unifiedpatents.com/insights/2026/1/13/patent-dispute-report-2025-in-review?utm_source=openai))
The Federal Circuit’s decisions in 2025 have had a profound impact on patent law. Notably, the court tightened the written description doctrine, reversing jury verdicts in three separate cases. Additionally, it made equitable estoppel and prosecution laches nearly impossible to invoke as litigation defenses and signaled a new judicial willingness to dismiss patent damages claims for lack of evidence at the Daubert stage. ([law.berkeley.edu](https://www.law.berkeley.edu/research/bclt/bclt-legal-analysis/apli-d1-p1/?utm_source=openai))
At the Patent Trial and Appeal Board (PTAB), institution rates dipped sharply mid-year—falling to roughly 51% in Q2 2025 from about 67% in Q1 and 75% in the same quarter of 2024—intensifying the premium on front-end petition quality and forum coordination. As discretionary denials increased, parties adjusted their mix of options, with ex parte reexamination rising to more than a quarter of post-grant filings while the share of inter partes review declined. ([afslaw.com](https://www.afslaw.com/perspectives/alerts/trends-analysis-post-grant-proceedings-patent-litigation?utm_source=openai))
In terms of damages, the largest patent verdict of the year was Apple’s $634 million loss against Masimo. Juries issued eight other nine-figure verdicts in 2025, many of which were against Samsung. ([law360.com](https://www.law360.com/telecom/articles/2418879/the-top-patent-damages-of-2025?utm_source=openai))
These developments underscore a dynamic and evolving patent litigation environment in 2025, characterized by increased filings, significant damages awards, and judicial decisions that continue to shape the contours of patent law in the United States.